Stakeholders to Scope Out Value in GI Cancer TherapyStakeholders to Scope Out Value in GI Cancer Therapy

Dr John Marshall previews the upcoming 2015 Ruesch Symposium, in which policy makers, insurers, regulators, researchers, and patients debate about what therapies are worth pursuing in GI cancer. Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

Source: BMJ Comments - Category: General Medicine Source Type: forums
I think it is entirely appropriate to greet the advent of senolytics with enthusiasm. These treatments are the first legitimate rejuvenation therapies to successfully target one of the root causes of aging, the accumulation of lingering senescent cells in old tissues. The first human trial data is approaching publication, but even before it arrives, the evidence to date strongly suggests that meaningful levels of rejuvenation can be achieved in old people at a very low cost. The first senolytic drugs (such as dasatinib and navitoclax) and plant extracts (such as fisetin and piperlongumine) cost very little, and remove only...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Substitutable Medical Apps, Reusable Technologies (SMART) apps have been developed to meet the need for responsiveness in healthcare IT. In this video, Stefanie Krens, MSc, of Radboud University Medic... Author: VJOncology Added: 10/15/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Sangram Raut, Linda Mooberry, Nirupama Sabnis, Ashwini Garud, Akpedje Serena Dossou, Andras Lacko
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Authors: Botti G, Cantile M PMID: 30303033 [PubMed - as supplied by publisher]
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
The number of elderly people with advanced lung cancer is increasing globally owing to the aging population and advances in cancer therapy [1]. More than 50% of patients diagnosed with lung cancer are aged>65 years, which is the lower limit for defining “elderly” in epidemiologic researches [2]. Non-small-cell lung cancer (NSCLC) accounts for 85% of all cases of lung cancer among both the elderly [3] and the adults. Although platinum-combination regimens including newer agents are the standard first-line chemotherapy for most patients with adva nced NSCLC, their use in elderly patients remains controversial [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
Paolo Ciana Oncolytic viruses (OV) are engineered to infect, replicate in and kill cancer cells. Currently, the OV therapeutic approach is mainly restricted to neoplasia amenable to direct local administration of viral particles, while the possibility of a systemic delivery of cancer-tropic viruses would extend the OV application to the treatment of metastatic neoplasia. Herein, we applied in vivo/ex vivo imaging to demonstrate that cancer tropism is achieved when OV are encapsulated inside extracellular vesicles (EV) administered intravenously (i.v.), but not when injected intraperitoneally (i.p.). Moreover, we show t...
Source: Viruses - Category: Virology Authors: Tags: Brief Report Source Type: research
Publication date: Available online 12 October 2018Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Arseniy E. Yuzhalin, Su Yin Lim, Anton G. Kutikhin, Alex N. Gordon-WeeksAbstractThe main cause of cancer-related mortality, metastasis, is a complex, multi-step process. The extracellular matrix (ECM) component of solid tumors has been implicated in metastatic progression; however, the ECM exists as a complex macromolecular substrate and it is unclear how its molecular composition promotes cancer progression. ECM homeostasis is regulated by various secreted proteins including cross-linkers (e.g., lysy...
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research
Authors: Schanz M, Schricker S, Pfister F, Alscher MD, Kimmel M Abstract Cancer patients often exhibit preexisting renal impairment and are simultaneously at risk for developing further kidney injury due to direct or indirect complications of oncological therapies. The nature of kidney injury is highly dependent on the therapy regimen used, and the spectrum of possible kidney stressors has widened as a result of the development of new therapeutic modalities such as molecular therapy or immunotherapy. Indirect renal complications are often due to volume depletion or other therapy-related side effects. Direct toxicit...
Source: Drugs of Today - Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
Publication date: Available online 11 October 2018Source: The Annals of Thoracic SurgeryAuthor(s): Hideki Ujiie, Lili Ding, Rong Fan, Tatsuya Kato, Daiyoon Lee, Kosuke Fujino, Tomonari Kinoshita, Chang Young Lee, Thomas K. Waddell, Shaf Keshavjee, Brian C. Wilson, Gang Zheng, Juan Chen, Kazuhiro YasufukuAbstractBackgroundWe have developed ultra-small porphyrin-lipoprotein nanoparticles (
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Hematology | Insurers